Inhibition of the PI3K/AKT/mTOR pathway in pancreatic cancer: is it a worthwhile endeavor?

被引：1
|
作者：
Ouissam, Al Jarroudi [1 ,2 ]
Hind, Chibani [1 ,2 ]
Aziz, Brahmi Sami [1 ,2 ]
Said, Afqir [1 ,2 ]
机构：
[1] Mohammed VI Univ Hosp, Dept Med Oncol, Oujda, Morocco
[2] Mohammed Ist Univ, Fac Med & Pharm, Oujda, Morocco
来源：
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY | 2024年 / 16卷
关键词：
clinical trials; genetic alterations; pancreatic ductal adenocarcinoma; PI3K/AKT/mTOR pathway; targeted therapy; GROWTH-FACTOR RECEPTOR; 1ST-IN-HUMAN PHASE-I; PHOSPHATIDYLINOSITOL 3-KINASE INHIBITOR; ACTIVATED PROTEIN-KINASE; NF-KAPPA-B; PI3K INHIBITOR; PHOSPHOINOSITIDE; 3-KINASE; PI3K/MTOR INHIBITOR; ANTITUMOR-ACTIVITY; BUPARLISIB BKM120;
D O I：
10.1177/17588359241284911
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Pancreatic cancer (PC) is an aggressive disease that is challenging to treat and is associated with a high mortality rate. The most common type of PC is pancreatic ductal adenocarcinoma (PDAC), and the existing treatment options are insufficient for PDAC patients. Due to the complexity and heterogeneity of PDAC, personalized medicine is necessary for effectively treating this illness. To achieve this, it is essential to understand the mechanism of PDAC carcinogenesis. Targeted therapies are a promising strategy to improve patient outcomes. Aberrant activation of the phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) signaling pathway plays a crucial role in PC pathogenesis, from initiation to progression. This review provides a comprehensive overview of the current state of knowledge regarding the PI3K pathway in PDAC, summarizes clinical data on PI3K pathway inhibition in PDAC, and explores potential effective combinations that are a promising direction requiring further investigation in PDAC.
引用
收藏
页数：21
相关论文
共 50 条
  • [1] Prospects of targeting PI3K/AKT/mTOR pathway in pancreatic cancer
    Mortazavi, Motahareh
    Moosavi, Fatemeh
    Martini, Miriam
    Giovannetti, Elisa
    Firuzi, Omidreza
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2022, 176
  • [2] Vertical inhibition of the PI3K/Akt/mTOR pathway is synergistic in breast cancer
    S-U Woo
    T Sangai
    A Akcakanat
    H Chen
    C Wei
    F Meric-Bernstam
    Oncogenesis, 2017, 6 : e385 - e385
  • [3] Vertical inhibition of the PI3K/Akt/mTOR pathway is synergistic in breast cancer
    Woo, S-U
    Sangai, T.
    Akcakanat, A.
    Chen, H.
    Wei, C.
    Meric-Bernstam, F.
    ONCOGENESIS, 2017, 6 : e385 - e385
  • [4] Inhibition of PI3K/AKT/mTOR pathway for the treatment of endometriosis
    Barra, Fabio
    Desideri, Lorenzo Ferro
    Ferrero, Simone
    BRITISH JOURNAL OF PHARMACOLOGY, 2018, 175 (17) : 3626 - 3627
  • [5] Inhibition of the PI3K/AKT/mTOR Pathway in Solid Tumors
    LoRusso, Patricia Mucci
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (31) : 3803 - +
  • [6] Activation of PI3K/Akt/mTOR Pathway and Dual Inhibitors of PI3K and mTOR in Endometrial Cancer
    Chen, Jiezhong
    Zhao, Kong-Nan
    Li, Rui
    Shao, Renfu
    Chen, Chen
    CURRENT MEDICINAL CHEMISTRY, 2014, 21 (26) : 3070 - 3080
  • [7] The PI3K/AKT/MTOR signaling pathway: The role of PI3K and AKT inhibitors in breast cancer
    Huemer F.
    Bartsch R.
    Gnant M.
    Current Breast Cancer Reports, 2014, 6 (2) : 59 - 70
  • [8] A Novel Natural Compound to Target PI3K/AKT/mTOR Pathway in Pancreatic Cancer
    Totiger, T.
    Srinivasan, S.
    Jala, V.
    Castellanos, J.
    Lamichhane, P.
    Dai, X.
    Vansaun, M.
    Merchant, N.
    Nagathihalli, N.
    PANCREAS, 2017, 46 (10) : 1440 - 1440
  • [9] Targeted Therapy for Advanced Prostate Cancer: Inhibition of the PI3K/Akt/mTOR Pathway
    Morgan, Todd M.
    Koreckij, Theodore D.
    Corey, Eva
    CURRENT CANCER DRUG TARGETS, 2009, 9 (02) : 237 - 249
  • [10] PI3K/Akt/mTOR pathway as a target for cancer therapy
    Morgensztern, D
    McLeod, HL
    ANTI-CANCER DRUGS, 2005, 16 (08) : 797 - 803
12345